OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome wherein small tumors secrete excess fibroblast growth factor 23 (FGF23) leading to hypophosphatemia, osteomalacia, bone pain, fractures, and muscle weakness. Burosumab is an anti-FGF23 monoclonal antibody approved for treatment of TI...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Thomas, Cimms, Tricia, Hetzer, Joel, Insogna, Karl, Kumar, Rajiv, Merritt II, J Lawrence, Miller, Paul, Peacock, Munro, Rauch, Frank, Stanciu, Irinel, Weber, Thomas, Jan De Beur, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Bone & Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624705/
http://dx.doi.org/10.1210/jendso/bvac150.394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624705/
http://dx.doi.org/10.1210/jendso/bvac150.394

Ejemplares similares